However, despite the excellent efficacy of anti-PD-1 in melanoma compared to other tumors, many patients still develop primary and secondary drug resistance, resulting in a low objective response rate (ORR) ranging from 16.6% to 38% 7-10. This evidence concerns the gene PDCD1 and melanoma.